Science team designs a new CAR they say may work much better than BCMAs in fighting multiple myeloma
Right now the big R&D play in the multiple myeloma field is centered around a raft of experimental BCMA approaches, including CAR-Ts. But a scientific team at the University of Utah says they may have found a better approach.
Focusing on the high rate of relapse using current therapies, as well as the waning efficacy of the clinical CAR-Ts, a team at the Huntsman Cancer Institute at the University of Utah built a new CAR focused on CD229.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
